ArticleCancer medicine2026
Development of a Risk Prediction Model for Bone Metastasis in Lung Adenocarcinoma With a T1 Primary Tumor Based on Intratumoral and Peritumoral Radiomics.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeBone metastasis significantly affects the prognosis of lung adenocarcinoma (LUAD) patients. This study aims to construct and validate a risk prediction model for bone metastasis in LUAD with a T1 primary tumor based on intratumoral and peritumoral radiomics features. MATERIALS AND
methodsA total of 392 patients pathologically diagnosed with LUAD and a T1 primary tumor from two medical centers were retrospectively included (training cohort: n = 217, internal validation cohort: n = 93, external validation cohort: n = 82). Univariate and multivariate analyses identified independent risk factors for the clinicoradiologic model. Radiomics features were extracted from the gross tumor volume (GTV) and peritumoral tumor volume (PTV) in the training cohort CT images to establish intratumoral and peritumoral radiomics models. The optimal radiomics model was combined with clinicoradiologic features to develop a nomogram. Model performance was assessed using the area under the curve (AUC), calibration curves, and decision curve analysis (DCA).
resultsAmong 392 LUAD patients with a T1 primary tumor, 147 had bone metastasis. The clinicoradiologic model incorporated three predictors: lymph node enlargement, pleural effusion, and carcinoembryonic antigen (CEA) levels. The PTV (-3 to 3 mm) radiomics model showed high discrimination performance, with an AUC of 0.810 (95% CI: 0.712-0.908) in the external validation cohort. The nomogram model demonstrated the highest discrimination performance, with an AUC of 0.884 (95% CI: 0.715-0.946), and showed acceptable calibration.
conclusionIn this retrospective two-center cohort of patients with LUAD and a T1 primary tumor, the combined clinicoradiologic-radiomics nomogram showed potential for stratifying the risk of synchronous bone metastasis at baseline evaluation. Further validation in larger and more representative cohorts is warranted before broader clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.